Dear Doctor Letter (Rote-Hand-Brief) on Gilenya® (fingolimod): Recommendations revised in analogy to the recommendations for first use regarding cardiovascular monitoring in case of renewed treatment
2013.01.08
Active substance: fingolimod
Revised recommendations on repeated cardiovascular monitoring in case of renewed treatment with Gilenya®. These recommendations apply for patients following interruption of treatment and for patients with bradyarrhythmia requiring therapy following initial treatment with Gilenya®.
Additional information:
(SPC/PIL - available in German only)
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN